Effective Evaluation of Intravenous Ribavirin Therapy of Epidemic Hemorrhagic Fever by a Prospective, Double-Blind, Concurrent, Randomized and Placebo-Controlled Design.
Final rept. 1 Nov 85-31 Oct 90,
HUBEI MEDICAL COLL (CHINA) VIRUS RESEARCH INST
Pagination or Media Count:
A prospective, randomized, double-blind, concurrent, placebo controlled, clinical trial of intravenous ribavirin was conducted in patients with epidemic hemorrhagic fever in Wuchang, Hubei, the Peoples Republic of China. Comparability of treatment groups at baseline was demonstrated. Mortality was significantly reduced a seven fold decrease in risk of death among ribavirin treatmented patients when comparisons were adjusted for baseline risk estimators of mortality p0.01, 2 tailed. Hemorrhagic fever with renal syndrome typically consists of five consecutive, but frequently overlapping, clinical phases. Occurrence of the oliguric and hemorrhage phases was associated with severity of clinical disease in the placebo group. Ribavirin therapy resulted in a significant reduction in 1 the risk of entering the oliguric phase, 2 serum creatinine levels, 3 duration of hypertension, 4 the risk of experiencing hemorrhage, and 5 death. The only ribavirin related side effect was anemia. Which was fully recovered following completion of therapy.
- Medicine and Medical Research